Arrow-right Camera
Sports >  MLB

Mexican player Japhet Amador suspended in Japan for doping

In this July 28, 2018, photo, Rakuten Eagles' Japhet Amador of Mexico hits a solo home run against the SoftBank Hawks in the seventh inning of their regular season baseball game in Fukuoka, southern Japan. Amador was suspended for six months by Nippon Professional Baseball (NPB) for a doping violation. The 31-year-old slugger, who has been out since Aug. 3 with abdominal pain, tested positive for the banned substances chlorthalidone and furosemide, NPB said on Thursday, Aug. 9, 2018. (AP)
In this July 28, 2018, photo, Rakuten Eagles' Japhet Amador of Mexico hits a solo home run against the SoftBank Hawks in the seventh inning of their regular season baseball game in Fukuoka, southern Japan. Amador was suspended for six months by Nippon Professional Baseball (NPB) for a doping violation. The 31-year-old slugger, who has been out since Aug. 3 with abdominal pain, tested positive for the banned substances chlorthalidone and furosemide, NPB said on Thursday, Aug. 9, 2018. (AP)

TOKYO – Mexican infielder Japhet Amador has been suspended for six months by Nippon Professional Baseball for a doping violation.

The 31-year-old slugger, who has been out since Aug. 3 with abdominal pain, tested positive for the banned substances chlorthalidone and furosemide, NPB said on Thursday.

Both are diuretic drugs used in the treatment of high blood pressure. Diuretics are banned because they can be used to mask the presence of performance-enhancing substances in the bloodstream.

Amador denied knowingly taking a banned substance at a hearing in July but did not file an appeal over the test results.

In 62 games for the Rakuten Eagles this year, Amador posted a .269 batting average with 20 home runs.

Amador joined the Eagles in 2016, a year after leading the Mexican Baseball League in home runs.


Subscribe to The Spokesman-Review’s sports newsletter

Get the day’s top sports headlines and breaking news delivered to your inbox by subscribing here.

There was a problem subscribing you to the newsletter. Double check your email and try again, or email webteam@spokesman.com

You have been successfully subscribed!